PHARMACY MARKET

Fusion Pharmaceuticals has Signed an Agreement to Build a Radiopharmaceutical Manufacturing Facility

Anurag Khadkikar | June 03, 2021

Fusion Pharmaceuticals has Signed an Agreement to Build a Radiopharmaceutical Manufacturing Facility
Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines; today announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University, to build a 27,000 square foot Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility. The facility, to be made by McMaster and equipped and validated by Fusion, will be designed to support the manufacturing of the Company's growing pipeline of targeted alpha therapies (TATs). Fusion expects the manufacturing facility will be operational by early 2024.

"Manufacturing and supply chain are critical components of radiopharmaceutical development and commercialization, and with Fusion's expertise, we believe we are well-positioned to create a facility to scale production in support of our growing pipeline and development collaborations," said Fusion Chief executive officer John Valliant, Ph.D. "We will continue to prioritize manufacturing and supply chain infrastructure in our long-term plans, and this facility is an important milestone in executing those plans. The location of the facility, adjacent to our internal research organization and a world-class University that specializes in medical isotope research and training, enables us to efficiently advance new TATs and hire top-tier talent to support our leading portfolio of radiopharmaceuticals."

In conjunction with the execution of the lease agreement, Fusion has entered into a services agreement with its long-time partner, the Centre for Probe Development and Commercialization (CPDC), to provide services relating to certain aspects of the validation of this new manufacturing facility.

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules to deliver the alpha-emitting payloads to tumors selectively.

Spotlight

To manage chronic medical conditions, real-time monitoring of disease-specific physiologic metrics is becoming an important part of standard of care, and smartphone technology is making it possible. Existing smartphone interfacing devices now record health parameters and metrics on diseases such as


Other News

PHARMACY MARKET

MEDISCA Chooses Creatio to Speed Up Operations and Increase Market Share

MEDISCA | June 18, 2021

MEDISCA has chosen Creatio's low-code platform for process management and CRM, the company said today. MEDISCA, a global leader in pharmaceutical compounding, chose Creatio to speed up processes, improve market share among current partners, and boost revenue per employee. MEDISCA assists pharmacists by supplying equipment, devices, and high-quality ingredients. MEDISCA has a good reputation in the pharmaceutical compounding business as an innovative and entrepreneurial company with 32 years of experience. The company's top priority is to automate processes throughout its sales, service, and marketing divisions and replace at least five disparate systems. ...

Read More

PHARMACY MARKET

Rx-360 Launches New auditsPlus®

Rx-360 | June 10, 2021

Rx-360, a global pharmaceutical consortium committed to supply chain integrity and patient safety, is happy to announce the extension of our Audit Program. The release of the new Rx-360 auditsPlus database is the key driver of this growth. This interactive, user-friendly database will not only raise awareness of the Rx-360 Joint Audit Program®. Still, it will also provide Rx-360 program users with new and improved tools to minimize their audit burden. Rx-360's CEO, Jim Fries, stated, "Maintaining quality in pharmaceutical materials is an ever-increasing problem for the pharmaceutical sector. To maintain our commitment to patient safety, this new tool will provide ...

Read More

RESEARCH

Moderna and Medison Pharma Collaborate to Commercialize Moderna's COVID-19 Vaccine in Central Eastern Europe and Israel

Moderna | June 08, 2021

Moderna, Inc., a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines, and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, announced today a new agreement to commercialize the Moderna COVID-19 Vaccine in Central Eastern Europe and Israel. Poland, Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia, and Herzegovina, Kosovo, North Macedonia, Montenegro, and Israel are among the nations included by the pact. "We are excited to work with Moderna in 20 markets, covering over 175 million p...

Read More

BUSINESS INSIGHTS

CATO SMS Acquires Nuventra in order to Expand its Drug Development Offering Into Clinical Pharmacology

Nuventra, CATO SMS | May 27, 2021

CATO SMS, a global provider of regulatory and clinical research services, announced today the acquisition of Nuventra, Inc., to expand its offering into the critical area of clinical pharmacology. Nuventra, headquartered in Durham, North Carolina, is a leading company in clinical pharmacology science and services. The acquisition expands CATO SMS's portfolio of specialized solutions that help biopharmaceutical companies with drug development by providing a key set of skills targeted at significantly reducing development risk, costs, and timelines. CATO SMS now provides customers cutting-edge clinical pharmacology services such as strategic consulting, pharmacokinetics/phar...

Read More

Spotlight

To manage chronic medical conditions, real-time monitoring of disease-specific physiologic metrics is becoming an important part of standard of care, and smartphone technology is making it possible. Existing smartphone interfacing devices now record health parameters and metrics on diseases such as

Resources

Events